HER2‐positive (Erb‐B2 overexpressing) and basal‐like subtypes originally showed a poorer prognosis than luminal types (hormone receptor‐positive cancers) 7, but the prognosis of HER2‐positive invasive breast cancers has improved dramatically with targeted anti‐HER2 therapies such as trastuzumab 8. This evidence concerns the gene ERBB2 and invasive breast carcinoma.